ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Infection"

  • Abstract Number: 0648 • ACR Convergence 2021

    Improving Post-Rituximab Hypogammaglobulinemia Risk Assessments: A Fellows’ Quality Improvement Initiative

    Beth Rutstein1, Melissa Argraves2, Atiye Bilgic Dagci2, Sarah Bayefsky2, Julia Rood2, Julie Chase3, Jay Mehta2, Melissa Lerman2, Cory Stingl4 and Jon Burnham2, 1Children's Hospital of Philadelphia, Wynnewood, PA, 2Children's Hospital of Philadelphia, Philadelphia, PA, 3The Children's Hospital of Philadelphia, Philadelphia, PA, 4Children's Hospital of Philadelphia, Durham, NC

    Background/Purpose: Hypogammaglobulinemia following rituximab therapy is a potentially severe complication that can lead to infection-related morbidity and mortality. If recognized, clinicians may prevent infections by…
  • Abstract Number: 1542 • ACR Convergence 2021

    Does Adjustment to Dosing and Timing of Immunomodulatory Drugs Impact Immunogenicity of COVID19 Vaccines in Patients with Autoimmune and Inflammatory Rheumatic Disease (AIIRD)?

    Andrew Laster1, Gordon Lam1, Sarah McCarter1, Heather Gladue2, Ahmad Kashif1, Erin Siceloff1, Victoria Lackey2, Cheryl Robertson2, Ashley Toci1 and Leonard Calabrese3, 1Arthritis and Osteoporosis Consultants of the Carolinas, Charlotte, NC, 2Arthritis & Osteoporosis Consultants of the Carolinas, Charlotte, NC, 3Cleveland Clinic, Cleveland, OH

    Background/Purpose: Clinical trials leading to approval of the COVID19 vaccines did not include immunocompromised individuals. Concerns have been raised that immunogenicity of the vaccines may…
  • Abstract Number: 0802 • ACR Convergence 2021

    Infection in Rheumatoid Arthritis Patients Treated with Golimumab

    Louis Bessette1, Proton Rahman2, John Kelsall3, Jane Purvis4, Emmanouil Rampakakis5, Allen Lehman6, Meagan Rachich6, Francois Nantel7 and Odalis Asin-Milan6, 1Laval University, Québec City, QC, Canada, 2Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, 3Providence Health Care, Vancouver, BC, Canada, 4Peterborough Education, Peterborough, ON, Canada, 5JSS Medical Research, Montréal, QC, Canada, 6Janssen Inc., Toronto, ON, Canada, 7., Montreal, ON, Canada

    Background/Purpose: Biologic use in RA is a well-characterized risk factors for infections. The aim of this analysis was to characterize the incidence of infection in…
  • Abstract Number: 1548 • ACR Convergence 2021

    Q Fever as a Mimicker of Rheumatologic Conditions: A Case Series from Two Tertiary Care Academic Centers in Southern California

    Manushi Aggarwal and Marven Cabling, Loma Linda University Health, Redlands, CA

    Background/Purpose: Q fever, an endemic disease in Southern California, is a zoonosis caused by Coxiella burnetii. The infection can present with multiple non-specific acute and chronic manifestations including fever, headache,…
  • Abstract Number: 0010 • ACR Convergence 2021

    Relaxed Peripheral Tolerance Drives Broad de Novo Autoreactivity in Severe COVID-19

    Matthew Woodruff1, Richard Ramonell2, Ankur Singh Saini2, Mark Rudolph3, F. Eun-Hyung Lee2 and Iñaki Sanz4, 1Emory University, Decatur, GA, 2Emory University, Atlanta, GA, 3Exagen Inc., Vista, CA, 4Emory University School of Medicine, Atlanta, GA

    Background/Purpose: An emerging feature of COVID-19 is the identification of autoreactivity in patients with severe disease that may contribute to disease pathology, however the origins…
  • Abstract Number: 0843 • ACR Convergence 2021

    Prevalence and Trends of Infections in Hospitalized Patients with Rheumatoid Arthritis in the United States

    Pushti Khandwala1, Anila Hussain2 and Devashish Desai1, 1Crozer Chester Medical Center, Glen Mills, PA, 2Crozer Chester Medical Center, Glen Mills

    Background/Purpose: Rheumatoid arthritis (RA) patients have a higher risk of developing infections as compared to the patients without the diagnosis, and this risk is further…
  • Abstract Number: 1550 • ACR Convergence 2021

    Flares and Side Effects After COVID-19 Vaccination in Patients with Rheumatic Diseases

    Anna Carbone, Gentiana Vukatana, Enrica Vandelli, Marica Trevisani, Elisa Rossi, Rita Mulè and Marco Fusconi, Rheumatology Unit, Azienda Ospedaliero-Universitaria Bologna, Bologna, Italy

    Background/Purpose: There is increasing interest in the safety of COVID-19 vaccination in patients with underlying chronic conditions. We investigated the rates of side effects and/or…
  • Abstract Number: 0088 • ACR Convergence 2021

    Evaluation of Patient Characteristics and Clinical Outcomes Among SARS‑CoV‑2‑Diagnosed Patients with and Without RA or PsA Treated with Systemic Therapies: A Retrospective Cohort Study Using US Optum® COVID-19 Electronic Health Record Data

    Jeffrey Curtis1, Xiaofeng Zhou2, Jinoos Yazdany3, Philip Robinson4, Yan Chen2, Ann Madsen2, Jamie Geier2 and Birgitta Benda2, 1Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, 2Pfizer Inc, New York, NY, 3University of California San Francisco, San Francisco, CA, 4Faculty of Medicine, The University of Queensland, Herston, Australia

    Background/Purpose: Patients with chronic rheumatic diseases are considered to be at increased risk for some infections, with prescribed immunomodulatory (IM) therapies increasing this risk further.…
  • Abstract Number: 0862 • ACR Convergence 2021

    Prevalence and Risk Factors for Herpes Zoster Reactivation in 1542 Patients with Rheumatic Diseases

    Chi Chiu Mok1, Ling Yin Ho2, Sau Mei TSE2, Kar Li Chan3 and Chi Hung To4, 1Tuen Mun Hospital, Hong Kong, China, 2Tuen Mun Hospital, Hong Kong, Hong Kong, 3Tuen Mun Hospital, Hong Kong, 4Pok Oi Hospital, Hong Kong, Hong Kong

    Background/Purpose: To study the prevalence and risk factors of herpes zoster (HZ) infection in patients with rheumatic diseases.Methods: Medical records of patients with rheumatic diseases…
  • Abstract Number: 1554 • ACR Convergence 2021

    COVID-19 Vaccine Hesitancy Among Patients with Rheumatic and Other Diseases

    Valeria Valerio1, Emmanouil Rampakakis2, Marie Hudson3, Sasha Bernatsky3, Elizabeth M. Hazel3 and Ines Colmegna4, 1Research Institute of the McGill University Health Centre, Montréal, QC, Canada, 2JSS Medical Research, Montréal, QC, Canada, 3McGill University, Montréal, QC, Canada, 4The Research Institute of the McGill University Health Centre, Montréal, QC, Canada

    Background/Purpose: Vaccination is fundamental to reduce COVID-19 risk and its complications. Vaccine hesitancy is a threat to COVID-19 vaccination uptake. We assessed the frequency of…
  • Abstract Number: 0098 • ACR Convergence 2021

    Patients with Chronic Inflammatory Rheumatic Diseases Report a Lower Frequency of Infections Than Controls and They Protect Themselves Well Against SARS-CoV-2 Transmission

    Iulia Roman, Ioana Andreica, Xenofon Baraliakos, Uta Kiltz and Juergen Braun, Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany

    Background/Purpose: The SARS-CoV-2 pandemic has affected life in most countries around the world for more than a year now. It is not entirely clear if…
  • Abstract Number: 0937 • ACR Convergence 2021

    Evaluation of the Safety of Vedolizumab in Combination with Other Immunosuppression Biological Therapy in Patients with Inflammatory Bowel Disease

    Gino Chesini1, Elizabeth Parrott1, Lauren Fox1, Jenna Beatty1, Cassandra Effken1, Na Yu1, Florence Hosseini-Aslinia1 and Megan Krause2, 1University of Kansas Medical Center, Kansas City, KS, 2University of Kansas, Kansas City, KS

    Background/Purpose: Inflammatory bowel disease (IBD) causes a wide range of symptomology frequently leading to co-management of disease activity between gastroenterologist and rheumatologists. Recently in efforts…
  • Abstract Number: 1556 • ACR Convergence 2021

    Mortality Rate Related to COVID-19 in Rheumatic and Musculoskeletal Diseases (RMDs)

    Ines Perez - Sancristobal1, Dalifer Freites1, Leticia Lopez Pedraza2, Maria Paula Alvarez Hernandez1, Jose Ignacio Colomer3, Alfredo Madrid - Garcia2, Benjamin Fernandez1, Cristina Vadillo1, Luis Rodriguez Rodriguez4, Arkaitz Mucientes2, Leticia Leon - Mateos2 and Lydia Abasolo5, 1Hospital Clínico San Carlos, Reumathology, Madrid, Madrid, Spain, 2Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Reumathology, Madrid, Spain, 3Fundación para la Investigación Biomedica, Reumathology, Madrid, Spain, 4Hospital Clinico San Carlos, Madrid, Spain, 5Rheumatology Department, Hospital Clínico San Carlos, Madrid, Spain

    Background/Purpose: In patients with rheumatic and musculoskeletal diseases (RMDs) and infected with Covid – 19, a) we want to assess the mortality rate (MR) related…
  • Abstract Number: 0141 • ACR Convergence 2021

    Who Gets Influenza Vaccinations Prior to and After a Diagnosis of RA? Results from the Canadian Early Arthritis Cohort (CATCH)

    Viviane Ta1, Orit Schieir2, Marie-France Valois1, Ines Colmegna3, Carol Hitchon4, Louis Bessette5, Glen Hazlewood6, Carter Thorne7, Janet Pope8, Gilles Boire9, Diane Tin10, Edward Keystone11, Vivian Bykerk12, Susan Bartlett1 and CATCH Investigators13, 1McGill University, Montréal, QC, Canada, 2Canadian Early Arthritis Cohort Study, Montréal, QC, Canada, 3The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, 4University of Manitoba, Winnipeg, MB, Canada, 5Centre de l'Ostoporose et de Rhumatologie de Qubec, Québec City, QC, Canada, 6University of Calgary, Calgary, AB, Canada, 7Southlake Regional Health Centre, Newmarket, ON, Canada, 8University of Western Ontario, London, ON, Canada, 9Universite de Sherbrooke, Sherbrooke, QC, Canada, 10The Arthritis Program Research Group, Newmarket, ON, Canada, 11Keystone Consulting Enterprises Inc., Toronto, ON, Canada, 12Hospital for Special Surgery, New York, NY, 13Canadian Early Arthritis Cohort Investigators, Toronto, ON, Canada

    Background/Purpose: Annual influenza vaccination is recommended for adults with RA, but remains low in established RA. We examined influenza vaccination coverage in the year prior…
  • Abstract Number: 0963 • ACR Convergence 2021

    Immunogenicity of COVID-19 Vaccines in Patients with Autoimmune and Inflammatory Rheumatic Diseases (AIIRDs)

    Gordon Lam1, Andrew Laster2, Sarah McCarter2, Heather Gladue3, Ahmad Kashif2, Erin Siceloff2, Victoria Lackey3, Cheryl Robertson3, Ashley Toci2 and Leonard Calabrese4, 1Arthritis and Osteoporosis Consultants of the Carolinas, Cornelius, NC, 2Arthritis and Osteoporosis Consultants of the Carolinas, Charlotte, NC, 3Arthritis & Osteoporosis Consultants of the Carolinas, Charlotte, NC, 4Cleveland Clinic, Cleveland, OH

    Background/Purpose: AIIRD patients may have a blunted immune response to the COVID-19 vaccines, but this is largely uncharacterized as these individuals were not included in…
  • « Previous Page
  • 1
  • …
  • 13
  • 14
  • 15
  • 16
  • 17
  • …
  • 32
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology